This Week in Cardiology — May 28, 2026

Welcome to This Week in Cardiology. This week we're covering 10 notable papers spanning heart failure management, new insights into antithrombotic and lipid-lowering drugs, important findings in arrhythmia, and the practicalities of clinical practice. Let's dive in.

Heart Failure Management and Innovation

Our first theme is heart failure, where we look at a neutral remote monitoring trial, define the optimal potassium range, and explore the frontiers of regenerative medicine.

Starting with a major clinical trial, the ALLEVIATE-HF study published in the Journal of the American College of Cardiology tested a strategy of proactive, remote management [7]. Investigators implanted a Reveal LINQ insertable cardiac monitor, or ICM, in over 700 heart failure patients. Patients were randomized to an intervention arm, where a high-risk alert from the ICM would trigger a centrally managed, nurse-facilitated, protocolized diuretic regimen, or to an observation arm with standard care. The primary goal was to see if this early, data-driven intervention could improve outcomes.

Results

The primary efficacy endpoint was a complex 5-component hierarchical composite. The trial did not meet this endpoint, with a win ratio of 0.79 that was not statistically significant. In fact, the rate of cumulative cardiovascular death and heart failure events was numerically higher in the intervention group, though this also did not reach statistical significance. The intervention was found to be safe, with a very low rate of serious adverse events.

Conclusions

For clinicians, ALLEVIATE-HF is a neutral trial. This specific strategy of using an ICM alert to trigger a remote diuretic adjustment did not improve a composite of clinical and patient-reported outcomes. It serves as a reminder that simply having more data does not automatically lead to better outcomes; the implementation strategy is key, and this one did not prove successful.

While high-tech interventions are challenging, getting the basics right remains critical. A new individual patient data meta-analysis in the European Heart Journal addresses a fundamental question: what is the optimal serum potassium level in heart failure? [2] Researchers pooled data from 12 randomized trials, including over 32,000 patients with HFrEF and nearly 14,000 with HFpEF.

Results

In patients with HFrEF, there was a reverse J-shaped association with outcomes. Compared to a reference range of 4.0 to 4.5 mmol/L, a potassium level below 3.5 was associated with a nearly 50% increased risk of all-cause mortality. The analysis showed that the lowest risk for all outcomes, including mortality and hospitalizations, occurred when baseline serum potassium was between 4.2 and 5.0 mmol/L. Interestingly, even mild hyperkalemia, defined as 5.0 to 5.5 mmol/L, was not associated with worse outcomes in the HFrEF group. For HFpEF, the risk curve was flatter, but the lowest incidence of adverse events was observed in the very same range: 4.2 to 5.0 mmol/L.

Conclusions

This large-scale analysis provides a clear, actionable target. For patients with either HFrEF or HFpEF, the optimal serum potassium concentration appears to be between 4.2 and 5.0 mmol/L. The findings reinforce the importance of avoiding hypokalemia, particularly in HFrEF.

Looking far into the future of heart failure therapy, The New England Journal of Medicine published a phase 1-2 study on a novel biologic ventricular assist tissue, or BioVAT [3]. This therapy involves surgically implanting engineered heart muscle, created from allogeneic induced pluripotent stem cells, onto the hearts of patients with advanced HFrEF. The study enrolled 20 patients who received the BioVAT grafts along with immunosuppression.

Results

This was an interim analysis at 3 months for a subset of 12 patients who received the highest dose. The results showed a statistically significant increase in target heart-wall thickness of 4.5 millimeters and an increase in left ventricular ejection fraction of 3.9 percentage points. There was also a trend toward improvement in the Kansas City Cardiomyopathy Questionnaire score. However, the safety profile is notable: all patients experienced at least one adverse event, and there were three deaths during the study, though not all were directly related to the procedure. Four other patients discontinued immunosuppression for various reasons, including device implantation or cancer.

Conclusions

This is very early, first-in-human data. While the improvements in wall thickness and LVEF are intriguing, the small sample size, open-label design, and significant adverse event rate mean this is still highly investigational. It represents a potential new frontier in cardiac remuscularization, but much longer-term follow-up and larger trials are needed. Also in preclinical news, a study in Cardiovascular Research identified the transcription factor RUNX1 as a potential therapeutic target in HFpEF, showing that its inhibition protected against diastolic dysfunction in a mouse model [10].

Antithrombotic and Lipid-Lowering Therapies

Next, we turn to two papers that refine our use of common cardiovascular medications. First, a systematic review and meta-analysis in JAMA Cardiology provides new clarity on the choice of P2Y12 inhibitors after percutaneous coronary intervention [4]. Researchers analyzed data from 15 randomized trials including nearly 49,000 patients to compare the efficacy and safety of clopidogrel, ticagrelor, and prasugrel.

Results

The analysis delivered a clear hierarchy. Compared to clopidogrel, prasugrel significantly reduced the risk of major adverse cardiovascular events (MACE), driven by lower rates of myocardial infarction and stent thrombosis. Ticagrelor did not significantly reduce MACE compared to clopidogrel, although it did reduce stent thrombosis. When prasugrel was compared directly to ticagrelor, prasugrel was associated with a lower risk of MACE, MI, and stent thrombosis. On the safety side, ticagrelor was associated with a higher risk of major bleeding compared to clopidogrel, driven by an increase in intracranial hemorrhage. Prasugrel ranked first for preventing MACE, MI, and stent thrombosis.

Conclusions

The authors conclude that in patients undergoing PCI, prasugrel provided the optimal balance between efficacy and safety compared with both ticagrelor and clopidogrel. This meta-analysis provides strong evidence to guide clinical decision-making in this common scenario.

From antithrombotics to lipids, another paper in JAMA Cardiology reports an unexpected benefit of bempedoic acid [5]. This was a post-hoc analysis of the CLEAR Outcomes trial, which studied bempedoic acid in over 13,000 statin-intolerant patients. While the primary trial focused on atherosclerotic events, this analysis looked at the risk of venous thromboembolism, or VTE.

Results

Over a median follow-up of about 40 months, patients randomized to bempedoic acid had a significantly lower risk of VTE compared to those on placebo. There were 39 VTE events in the bempedoic acid group versus 67 in the placebo group, corresponding to a hazard ratio of 0.58, or a 42% relative risk reduction. This benefit was consistent for both deep vein thrombosis and pulmonary embolism individually.

Conclusions

This is a novel and interesting finding. While statins and PCSK9 inhibitors have previously been linked to reduced VTE risk, this is the first such evidence for bempedoic acid. It suggests a potential pleiotropic effect beyond LDL lowering. While this was a post-hoc analysis, the robust effect size suggests this warrants further investigation as a potential added benefit of bempedoic acid in high-risk, statin-intolerant patients.

Arrhythmias and Electrophysiology

Our next section focuses on arrhythmias, with a large study expanding the link between rhythm disorders and dementia, and a case series demonstrating a new diagnostic tool for a rare channelopathy.

For years, the arrhythmia-dementia link has been dominated by atrial fibrillation. A new study in the European Heart Journal argues that we need to think broader [9]. Using the UK Biobank cohort of nearly 400,000 participants followed for over 13 years, investigators looked at the association of multiple arrhythmia types with the risk of developing dementia.

Results

The study confirmed the known risk with AF, but importantly, it found that incident bradyarrhythmias, conduction blocks, and ventricular arrhythmias were also independently associated with an increased risk of all-cause, vascular, and Alzheimer's dementia. Furthermore, there was a dose-response relationship: the more types of arrhythmia a person had, the higher their dementia risk. This risk was particularly high for patients with both AF and a conduction block. Brain MRI analysis supported the clinical findings, showing arrhythmia-related neurodegenerative changes like brain atrophy and white matter injury.

Conclusions

This paper significantly expands our understanding of the brain-heart connection. The key takeaway for clinicians is that the dementia risk associated with arrhythmias is not exclusive to AF. The presence of any major arrhythmia—and especially multiple types—should be considered a risk factor for cognitive decline and may warrant more aggressive management and counseling.

From large populations to rare diseases, a case series in JAMA Cardiology highlights a clinical breakthrough in diagnosing Calcium Release Deficiency Syndrome, or CRDS [6]. This is a newly described inherited arrhythmia caused by loss-of-function variants in the RYR2 gene, which can lead to unexplained sudden cardiac death. Previously, diagnosis required complex in-vitro testing.

The Study

This report describes a large family with a history of sudden death. Investigators used a recently proposed clinical provocation test involving burst pacing. The study examined 5 family members who were carriers of a novel RYR2 variant. The diagnostic hallmark they looked for was T-wave augmentation on the ECG immediately following the burst pacing or a spontaneous arrhythmia, a phenomenon that is pause-dependent.

Results

All 5 variant carriers demonstrated the diagnostic T-wave augmentation after pacing, clinically establishing the diagnosis of CRDS. This is the first report of this test being successfully used for clinical diagnosis in a family. Functional studies confirmed their novel variant was indeed a loss-of-function type.

Conclusions

This case series provides crucial real-world validation for a new clinical tool. For a rare and potentially lethal condition like CRDS, having a non-invasive provocation test that can be performed in the EP lab is a major step forward, potentially allowing for earlier diagnosis and risk stratification in affected families.

Clinical Practice and The Profession

Finally, we cover two papers grounded in the realities of daily practice and the future of our profession.

First, a highly practical network meta-analysis from JAMA helps answer a common question: which blood pressure drugs are best tolerated? [1] Poor tolerability is a major driver of non-adherence and poor BP control. This analysis synthesized data from 716 randomized trials and over 159,000 participants to compare discontinuation rates due to adverse events across the five major classes of BP drugs and their combinations.

Results

Compared to placebo, the drugs most likely to cause discontinuation due to adverse events were calcium channel blockers (CCBs), the combination of an ACE inhibitor plus a CCB, and the combination of a beta-blocker plus a thiazide diuretic. Perhaps most surprisingly, several regimens were actually better tolerated than placebo. All angiotensin II receptor blocker (ARB)-containing regimens had fewer treatment discontinuations than placebo, with ARB monotherapy and ARBs combined with CCBs showing statistically significant reductions in discontinuation. The authors suggest this may indicate a net symptomatic improvement, for example, through reduction in headache, which was seen with all classes except CCBs.

Conclusions

This study provides valuable data for personalizing hypertension therapy from the outset. While efficacy is paramount, these findings suggest that for improving adherence and long-term control, ARB-based regimens may be an excellent starting point due to their superior tolerability profile, which in some cases appears to be even better than taking a placebo.

Lastly, a perspective piece from the Journal of the American College of Cardiology looks at the health of our own profession [8]. Written by the Association of Professors of Cardiology Emerging Leaders Group, the paper outlines the mounting threats to the sustainability of academic cardiovascular medicine. It highlights the pressures on early-career faculty, including rising clinical demands, widening pay gaps with private practice, constrained research funding, and administrative burden. The authors argue that financial pressures are causing academic centers to prioritize short-term clinical revenue over the long-term investments in research and education that have historically driven the field forward. The piece serves as a call to action, proposing a roadmap of actionable strategies to revitalize the academic cardiology workforce and ensure a strong pipeline of future leaders.

Editor's Pick

If you only have time for one paper this week, make it the meta-analysis of P2Y12 inhibitors in JAMA Cardiology [4]. For the common clinical decision of choosing an antiplatelet agent after PCI, this paper provides a clear, evidence-based hierarchy, suggesting prasugrel offers the best balance of ischemic benefit and safety compared to ticagrelor and clopidogrel.

Clinical Bottom Line

Here are the key takeaways from this week in Cardiology.

First: For post-PCI patients, a new meta-analysis suggests prasugrel provides the best combination of ischemic benefit and safety compared to ticagrelor and clopidogrel.

Second: In heart failure, aim for a serum potassium between 4.2 and 5.0 mmol/L. A large patient-level meta-analysis identifies this as the optimal range for minimizing mortality risk in both HFrEF and HFpEF.

Third: The link between arrhythmia and dementia extends beyond atrial fibrillation. Bradyarrhythmias, conduction blocks, and ventricular arrhythmias also confer risk, and this risk appears to be cumulative.

Fourth: When choosing an initial antihypertensive, consider that ARB-based regimens are often better tolerated than placebo, while calcium channel blockers are associated with higher rates of discontinuation due to side effects.

And finally: A remote monitoring strategy using an insertable cardiac monitor to guide diuretic therapy in heart failure patients did not improve outcomes in the ALLEVIATE-HF trial, a neutral result for this specific intervention.

That's your roundup for This Week in Cardiology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.